Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Propper

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
British Journal of Haematology|December 1, 1978
Energy reserve and cation composition of irreversibly sickled cells in vivoB E Glader, S E Lux, A Muller-Soyano, et al.
The New England Journal of Medicine|August 25, 1977
Continuous subcutaneous administration of deferoxamine in patients with iron overloadR D Propper, B Cooper, R R Rufo, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2011
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancerA Maraveyas, J Waters, R Roy, et al.
The New England Journal of Medicine|January 27, 1983
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTHS L Hauser, D M Dawson, J R Lehrich, et al.
British Journal of Cancer|October 17, 2003
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancerS Madhusudan, A Protheroe, D Propper, et al.
Cancer Research|August 27, 1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patientsP Thavasu, D Propper, A McDonald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerE R Brown, K A Charles, S A Hoare, et al.
British Journal of Cancer|May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinomaP G Corrie, W Qian, B Basu, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
British Journal of Haematology|December 1, 1978
Energy reserve and cation composition of irreversibly sickled cells in vivoB E Glader, S E Lux, A Muller-Soyano, et al.
The New England Journal of Medicine|August 25, 1977
Continuous subcutaneous administration of deferoxamine in patients with iron overloadR D Propper, B Cooper, R R Rufo, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2011
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancerA Maraveyas, J Waters, R Roy, et al.
The New England Journal of Medicine|January 27, 1983
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTHS L Hauser, D M Dawson, J R Lehrich, et al.
British Journal of Cancer|October 17, 2003
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancerS Madhusudan, A Protheroe, D Propper, et al.
Cancer Research|August 27, 1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patientsP Thavasu, D Propper, A McDonald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerE R Brown, K A Charles, S A Hoare, et al.
British Journal of Cancer|May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinomaP G Corrie, W Qian, B Basu, et al.
Pageof 2